Header Logo

Connection

Paul Clapham to Animals

This is a "connection" page, showing publications Paul Clapham has written about Animals.
Connection Strength

0.135
  1. Repik A, Richards KH, Clapham PR. The promise of CCR5 antagonists as new therapies for HIV-1. Curr Opin Investig Drugs. 2007 Feb; 8(2):130-9.
    View in: PubMed
    Score: 0.020
  2. Peters PJ, Due?as-Decamp MJ, Sullivan WM, Clapham PR. Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues. J Neuroimmune Pharmacol. 2007 Mar; 2(1):32-41.
    View in: PubMed
    Score: 0.020
  3. Richards KH, Clapham PR. Human immunodeficiency viruses: propagation, quantification, and storage. Curr Protoc Microbiol. 2006 Sep; Chapter 15:Unit15J.1.
    View in: PubMed
    Score: 0.019
  4. Willey SJ, Reeves JD, Hudson R, Miyake K, Dejucq N, Schols D, De Clercq E, Bell J, McKnight A, Clapham PR. Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells. J Virol. 2003 Jun; 77(11):6138-52.
    View in: PubMed
    Score: 0.015
  5. Bhattacharya J, Peters PJ, Clapham PR. CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. AIDS. 2003; 17 Suppl 4:S35-43.
    View in: PubMed
    Score: 0.015
  6. Clapham PR, McKnight ?. Cell surface receptors, virus entry and tropism of primate lentiviruses. J Gen Virol. 2002 Aug; 83(Pt 8):1809-1829.
    View in: PubMed
    Score: 0.015
  7. Wang S, Chou TH, Hackett A, Efros V, Wang Y, Han D, Wallace A, Chen Y, Hu G, Liu S, Clapham P, Arthos J, Montefiori D, Lu S. Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. Hum Vaccin Immunother. 2017 12 02; 13(12):2996-3009.
    View in: PubMed
    Score: 0.010
  8. Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, Wang S, Clapham P, Lu S. Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J Virol. 2011 May; 85(10):4927-36.
    View in: PubMed
    Score: 0.007
  9. Agrawal L, Maxwell CR, Peters PJ, Clapham PR, Liu SM, Mackay CR, Strayer DS. Complexity in human immunodeficiency virus type 1 (HIV-1) co-receptor usage: roles of CCR3 and CCR5 in HIV-1 infection of monocyte-derived macrophages and brain microglia. J Gen Virol. 2009 Mar; 90(Pt 3):710-722.
    View in: PubMed
    Score: 0.006
  10. Elvin SJ, Williamson ED, Scott JC, Smith JN, P?rez De Lema G, Chilla S, Clapham P, Pfeffer K, Schl?ndorff D, Luckow B. Evolutionary genetics: Ambiguous role of CCR5 in Y. pestis infection. Nature. 2004 Jul 22; 430(6998):417.
    View in: PubMed
    Score: 0.004
  11. Reynolds L, Ullman C, Moore M, Isalan M, West MJ, Clapham P, Klug A, Choo Y. Repression of the HIV-1 5' LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1615-20.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.